← Back to Clinical Trials
Recruiting NCT06770101

NCT06770101 Suicide Assessment and Feasible Evidence-based Treatments for Youth Living With HIV in Lilongwe

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06770101
Status Recruiting
Phase
Sponsor University of Pennsylvania
Condition HIV
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-07-01
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 13 Years
Max Age 19 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
Behavioral: Enhanced Friendship Bench + Safety PlanningAugmented usual care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-07-01 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall aim of this study is to determine the feasibility, fidelity, acceptability, and preliminary effectiveness of the Friendship Bench +Safety Planning intervention in reducing suicidal ideation and behaviors (SIBs) and improving HIV engagement amongst adolescents living with HIV (ALWH) when compared to augmented usual care.

Eligibility Criteria

Inclusion Criteria: * Age 13-19 * Diagnosed with HIV * Report current or historical suicidal ideation and behaviors (SIBs) on question 9 of the Patient Health Questionnaire modified for adolescents (PHQ-9-A) and the Ask Suicide-Screening questionnaire (ASQ) * Living in the clinic's catchment area with intention to remain for more than 1 year * Willing to provide consent (age 18+ or 16-17 years old and married and thereby considered emancipated minors per Malawi law) or assent with parental consent (age 13-17). Exclusion Criteria: * Refuse to participate * Refuse to be audio-taped for in-depth interviews

Contact & Investigator

Central Contact

Melissa Stockton, PhD

✉ melissaann.stockton@pennmedicine.upenn.edu

📞 1-419-340-7476

Principal Investigator

Melissa Stockton, PhD

PRINCIPAL INVESTIGATOR

University of Pennsylvania

Frequently Asked Questions

Who can join the NCT06770101 clinical trial?

This trial is open to participants of all sexes, aged 13 Years or older, up to 19 Years, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06770101 currently recruiting?

Yes, NCT06770101 is actively recruiting participants. Contact the research team at melissaann.stockton@pennmedicine.upenn.edu for enrollment information.

Where is the NCT06770101 trial being conducted?

This trial is being conducted at Lilongwe, Malawi, Lilongwe, Malawi, Lilongwe, Malawi, Lilongwe, Malawi.

Who is sponsoring the NCT06770101 clinical trial?

NCT06770101 is sponsored by University of Pennsylvania. The principal investigator is Melissa Stockton, PhD at University of Pennsylvania. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology